We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+25.43%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$16.7B
AUM Growth
+$1.38B
Cap. Flow
-$374M
Cap. Flow %
-2.25%
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$37.7M
2
PRME icon
Prime Medicine
PRME
+$18.6M
3
DNLI icon
Denali Therapeutics
DNLI
+$14.9M
4
REPL icon
Replimune Group
REPL
+$14.2M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$13M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$254M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$92.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$44M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$37.6M
5
RLMD icon
Relmada Therapeutics
RLMD
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$6.03B 36.21%
46,912,266
– –
INCY icon
2
Incyte
INCY
$25.5B
$2.9B 17.44%
36,154,971
+397
+0% +$30.4K
ONC
3
BeOne Medicines Ltd
ONC
$33.8B
$2.57B 15.41%
11,668,897
– –
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12B
$789M 4.74%
7,620,494
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$667M 4.01%
41,923,486
– –
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$605M 3.63%
4,954,855
+102,200
+2% +$11.9M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.5B
$448M 2.69%
1,545,113
+45,900
+3% +$4.49M
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.3B
$185M 1.11%
6,354,608
+291,906
+5% +$7.5M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.42B
$146M 0.88%
12,710,818
– –
IMCR icon
10
Immunocore
IMCR
$1.68B
$144M 0.86%
2,520,731
– –
AKRO
11
DELISTED
Akero Therapeutics
AKRO
$130M 0.78%
2,368,378
– –
REPL icon
12
Replimune Group
REPL
$413M
$125M 0.75%
4,578,280
+684,437
+18% +$14.2M
KOD icon
13
Kodiak Sciences
KOD
$2.4B
$124M 0.74%
17,310,490
– –
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$110M 0.66%
969,727
– –
ARGX icon
15
argenx
ARGX
$55B
$106M 0.64%
280,159
– –
ABCL icon
16
AbCellera Biologics
ABCL
$1.62B
$106M 0.64%
10,450,180
– –
KYMR icon
17
Kymera Therapeutics
KYMR
$8.59B
$71.9M 0.43%
2,879,825
– –
KDNY
18
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$66.4M 0.4%
2,534,102
– –
TRDA icon
19
Entrada Therapeutics
TRDA
$229M
$65.8M 0.4%
4,865,819
– –
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$63.9M 0.38%
1,409,784
– –
PRLD icon
21
Prelude Therapeutics
PRLD
$347M
$61.1M 0.37%
10,123,824
– –
CERS icon
22
Cerus
CERS
$575M
$58.6M 0.35%
16,067,558
– –
JBIO
23
Jade Biosciences
JBIO
$1.14B
$57.9M 0.35%
56,482
-77
-0.1% -$55.9K
IGMS
24
DELISTED
IGM Biosciences
IGMS
$53.7M 0.32%
3,156,102
– –
IMTX icon
25
Immatics
IMTX
$1.16B
$45.2M 0.27%
5,187,081
+763,350
+17% +$7.9M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Baker Bros. Advisors held 128 positions worth $16.7B, up 9.1% from $15.3B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q4 2022 filing shows 13 new, 17 increased, 8 reduced and 15 closed positions. Its largest new stake was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M. The largest sale was Global Blood Therapeutics, Inc., an estimated $254M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2022 buy was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M.
  • Baker Bros. Advisors added most to Denali Therapeutics in Q4 2022, an estimated $14.9M increase.
  • Baker Bros. Advisors's biggest Q4 2022 reduction was Travere Therapeutics, cutting an estimated $44M.
  • Baker Bros. Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $254M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $16.7B portfolio in Q4 2022.
  • Baker Bros. Advisors opened 13 new positions and closed 15 in Q4 2022.
  • Baker Bros. Advisors's portfolio value rose 9.1% quarter-over-quarter to $16.7B.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.